Finally, since erythropoietin increases the risk of vascular thrombosis, it could be argued that the concomitant use of this drug and thalidomide could have an additive effect on hypercoagulability, but according to Galli et al. [67] erythropoietin does not seem to increase the risk of thrombosis in myeloma patients receiving thalidomide. The gene discussed is EPO; the disease is thrombophilia.